- Home
- COLL vs MYI Comparison
COLL vs MYI Comparison
Compare COLL & MYI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- COLL
- MYI
- Stock Information
- Founded
- COLL 2002
- MYI 1992
- Country
- COLL United States
- MYI United States
- Employees
- COLL N/A
- MYI N/A
- Industry
- COLL Biotechnology: Pharmaceutical Preparations
- MYI Investment Bankers/Brokers/Service
- Sector
- COLL Health Care
- MYI Finance
- Exchange
- COLL Nasdaq
- MYI Nasdaq
- Market Cap
- COLL 864.7M
- MYI 723.2M
- IPO Year
- COLL 2015
- MYI N/A
- Fundamental
- Price
- COLL $30.23
- MYI $10.59
- Analyst Decision
- COLL Strong Buy
- MYI
- Analyst Count
- COLL 5
- MYI 0
- Target Price
- COLL $43.80
- MYI N/A
- AVG Volume (30 Days)
- COLL 321.1K
- MYI 256.7K
- Earning Date
- COLL 05-08-2025
- MYI 01-01-0001
- Dividend Yield
- COLL N/A
- MYI 4.81%
- EPS Growth
- COLL N/A
- MYI N/A
- EPS
- COLL 1.25
- MYI N/A
- Revenue
- COLL $664,283,000.00
- MYI N/A
- Revenue This Year
- COLL $20.00
- MYI N/A
- Revenue Next Year
- COLL $3.74
- MYI N/A
- P/E Ratio
- COLL $24.13
- MYI N/A
- Revenue Growth
- COLL 17.17
- MYI N/A
- 52 Week Low
- COLL $23.23
- MYI $9.32
- 52 Week High
- COLL $42.29
- MYI $11.70
- Technical
- Relative Strength Index (RSI)
- COLL 64.41
- MYI 47.43
- Support Level
- COLL $28.81
- MYI $10.66
- Resistance Level
- COLL $30.17
- MYI $10.75
- Average True Range (ATR)
- COLL 1.02
- MYI 0.10
- MACD
- COLL 0.37
- MYI 0.02
- Stochastic Oscillator
- COLL 93.13
- MYI 52.94
About COLL Collegium Pharmaceutical Inc.
Collegium Pharmaceutical Inc is a specialty pharmaceutical company. The company is engaged in developing and planning to commercialize abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. The DETERx platform technology is designed to maintain the extended-release and safety profiles of abused drugs in the face of various methods including chewing, crushing, and dissolving. Its product portfolio includes Jornay, Xtampza ER, which is an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta Products, which are extended-release and immediate-release formulations of tapentadol; Belbuca, and Symproic.
About MYI Blackrock MuniYield Quality Fund III Inc
BLACKROCK MUNIYIELD QUALITY FUND III, INC. is a investment management company. Its investment objective is to provide shareholders with a high level of current income exempt from U.S. federal income taxes as is consistent with its investment policies and prudent investment management. The company invests in various sectors such as Transportation; Utilities; Health; Education; Tobacco and others.